Novartis Ag (NVS) EPS (Basic) (QoQ) (2009 - 2023)
Novartis Ag (NVS) EPS (Basic) (QoQ) (2009 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.04 Bn | 633.28 Bn | 17.26 Bn |
| 2 | AbbVie | 470.61 Bn | 464.04 Bn | 12.70 Bn |
| 3 | Merck | 379.00 Bn | 371.86 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.30 Bn | 295.61 Bn | 11.24 Bn |
| 5 | Astrazeneca | 258.47 Bn | 253.57 Bn | 12.86 Bn |
| 6 | Amgen | 237.78 Bn | 223.79 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 183.75 Bn | 180.57 Bn | 6.22 Bn |
| 8 | Pfizer | 160.91 Bn | 149.21 Bn | 10.94 Bn |
| 9 | Gsk | 106.07 Bn | 101.90 Bn | 8.24 Bn |
| 10 | Sanofi | 55.31 Bn | 47.93 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 18,620.72% |
| Sep 30, 2023 | -99.52% |
| Jun 30, 2023 | 37,598.80% |
| Mar 31, 2023 | -99.76% |
| Dec 31, 2022 | 24,310.02% |
| Sep 30, 2022 | -99.61% |
| Jun 30, 2022 | -99.81% |
| Mar 31, 2022 | 50,157.00% |
| Dec 31, 2021 | 4,735.95% |
| Sep 30, 2021 | -97.41% |
| Jun 30, 2021 | -99.61% |
| Mar 31, 2021 | 24,638.17% |
| Dec 31, 2020 | -99.68% |
| Sep 30, 2020 | 33,352.37% |
| Jun 30, 2020 | 27,662.38% |
| Mar 31, 2020 | -99.65% |
| Dec 31, 2019 | 1,332.84% |
| Sep 30, 2019 | -108.82% |
| Jun 30, 2019 | 10,245.96% |
| Mar 31, 2019 | -99.37% |